NKTR Share Price

Open 21.75 Change Price %
High 22.50 1 Day 0.51 2.35
Low 21.28 1 Week 1.50 7.26
Close 22.17 1 Month 3.01 15.71
Volume 1859426 1 Year 6.78 44.05
52 Week High 24.88
52 Week Low 11.41
NKTR Important Levels
Resistance 2 23.30
Resistance 1 22.83
Pivot 21.98
Support 1 21.51
Support 2 21.04
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPWR 4.65 55.00%
LOCM 0.09 50.00%
VRTB 3500.00 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SRPT 40.93 20.10%
AEZS 2.80 19.66%
GEVO 0.71 18.33%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
QKLS 0.11 -47.62%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Nektar Therapeutics (NASDAQ: NKTR)

NKTR Technical Analysis 5
As on 20th Jul 2017 NKTR Share Price closed @ 22.17 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 16.52 & Strong Buy for SHORT-TERM with Stoploss of 19.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
NKTR Target for July
1st Target up-side 21.26
2nd Target up-side 22.46
3rd Target up-side 23.66
1st Target down-side 17.84
2nd Target down-side 16.64
3rd Target down-side 15.44
NKTR Other Details
Segment EQ
Market Capital 1016949312.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.nektar.com
NKTR Address
NKTR
455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
Phone: 415-482-5300
Fax: 415-339-5300
NKTR Latest News
Interactive Technical Analysis Chart Nektar Therapeutics ( NKTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nektar Therapeutics
NKTR Business Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is consisted of early to late stage drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve both small molecule and biologic drug candidates. It creates drug candidates by using its advanced polymer conjugate technologies to modify the chemical structure of pharmacophores to create new molecular entities. Its drug candidate, naloxegol (formerly known as NKTR-118), is an oral opioid antagonist, which has completed Phase III clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain. Its second drug candidate, etirinotecan pegol (also known as NKTR-102), is a topoisomerase I inhibitor, which is under Phase III clinical study as of December 31, 2012.